Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
BURLINGAME, Calif., March 13, 2017 -- Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, announced that the company will postpone its R&D Day scheduled for March 14, 2017 due to an anticipated severe winter snowstorm forecasted to hit the New York tri-state area and its impact on the travel schedule and participation of its principal presenters.
The company plans to reschedule the event within the first half of 2017 and will provide details of the rescheduled event as soon as that date is determined.
The company anticipates providing additional updates on its lead CPI-444 program as planned at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2017, which is taking place April 1-5 in Washington, D.C.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Tecentriq® is a registered trademark of Genentech.
Corvus Contact: Jason Coloma SVP, Chief Business Officer Corvus Pharmaceuticals, Inc. +1-650-900-4511 [email protected] Media Contact Julie Normart Pure Communications +1-415-946-1087 [email protected]
